Advertisement
EXEL vs PTCT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EXEL is a Hold and PTCT is a Hold.
EXEL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EXEL turned positive on October 09, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on EXEL as a result. In 67 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in 206 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 166 of 268 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
EXEL broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 23 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.897) is normal, around the industry mean (3.070). P/E Ratio (20.122) is within average values for comparable stocks, (-1.257). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (6.305) is also within normal values, averaging (439.237).
PTCT's RSI Indicator climbs out of oversold territory
The RSI Indicator for PTCT moved out of oversold territory on September 25, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 22 of the 27 cases the stock moved higher. This puts the odds of a move higher at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on PTCT as a result. In 60 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for PTCT just turned positive on October 20, 2026. Looking at past instances where PTCT's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Following a +3.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTCT advanced for three days, in 219 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PTCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for PTCT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-32.534) is normal, around the industry mean (3.070). PTCT has a moderately low P/E Ratio (-96.209) as compared to the industry average of (-1.257). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (6.094) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. PTCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
EXEL | PTCT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 1 Undervalued | |
PROFIT vs RISK RATING 1..100 | 4 | 60 | |
SMR RATING 1..100 | 23 | 100 | |
PRICE GROWTH RATING 1..100 | 37 | 70 | |
P/E GROWTH RATING 1..100 | 33 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 4 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PTCT's Valuation (1) in the Biotechnology industry is significantly better than the same rating for EXEL (90). This means that PTCT’s stock grew significantly faster than EXEL’s over the last 12 months.
EXEL's Profit vs Risk Rating (4) in the Biotechnology industry is somewhat better than the same rating for PTCT (60). This means that EXEL’s stock grew somewhat faster than PTCT’s over the last 12 months.
EXEL's SMR Rating (23) in the Biotechnology industry is significantly better than the same rating for PTCT (100). This means that EXEL’s stock grew significantly faster than PTCT’s over the last 12 months.
EXEL's Price Growth Rating (37) in the Biotechnology industry is somewhat better than the same rating for PTCT (70). This means that EXEL’s stock grew somewhat faster than PTCT’s over the last 12 months.
EXEL's P/E Growth Rating (33) in the Biotechnology industry is significantly better than the same rating for PTCT (100). This means that EXEL’s stock grew significantly faster than PTCT’s over the last 12 months.
| EXEL | PTCT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | 3 days ago 81% |
| Stochastic ODDS (%) | 1 day ago 55% | 1 day ago 72% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 71% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 74% |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 67% | 1 day ago 75% |
| Advances ODDS (%) | 2 days ago 68% | 1 day ago 79% |
| Declines ODDS (%) | 17 days ago 59% | 16 days ago 78% |
| BollingerBands ODDS (%) | 1 day ago 61% | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 62% | 1 day ago 76% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EXEL’s FA Score shows that 3 FA rating(s) are green while PTCT’s FA Score has 1 green FA rating(s).
- EXEL’s FA Score: 3 green, 2 red.
- PTCT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EXEL’s TA Score shows that 4 TA indicator(s) are bullish while PTCT’s TA Score has 5 bullish TA indicator(s).
- EXEL’s TA Score: 4 bullish, 4 bearish.
- PTCT’s TA Score: 5 bullish, 3 bearish.
Price Growth
EXEL (@Biotechnology) experienced а +1.36% price change this week, while PTCT (@Biotechnology) price change was +2.25% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.87%. For the same industry, the average monthly price growth was -11.05%, and the average quarterly price growth was -12.65%.
Reported Earning Dates
EXEL is expected to report earnings on Feb 09, 2027.
PTCT is expected to report earnings on Feb 23, 2027.
Industries' Descriptions
@Biotechnology (+1.87% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement